Payment overview · 2025
General Payments
$1,112.29
51 reported records · 21 companies
Healthcare provider profile · identity verified
Timothy John Corbin, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ALEXANDER CITY, AL · NPI 1013083062
Verified facts
What the public records show
CMS Open Payments records show Timothy John Corbin, M.D. received $1,112.29 in general payments during 2025 across 51 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 612 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tresiba by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 612 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $291.68 | 26.2% | 14 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $159.33 | 14.3% | 10 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $145.93 | 13.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.33 | 5.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.86 | 5.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.50 | 4.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.97 | 3.7% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $39.87 | 3.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.66 | 2.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $27.36 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.47 | 2.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.38 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.92 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.14 | 1.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.14 | 1.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.63 | 1.8% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.44 | 1.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.50 | 1.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.24 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.00 | 1.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.94 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,112.29 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $315.06 | 15 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $159.33 | 10 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $145.93 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $62.74 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.33 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.50 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $40.97 | 2 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $39.87 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.72 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.66 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $27.36 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 612 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 114 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
612 | 68 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
51 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
42 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
114 | 17 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
612 | 68 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1253 | 257 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1222 | 270 |
| Amlodipine Besylate | Amlodipine Besylate | 1097 | 233 |
| Pantoprazole Sodium | Pantoprazole Sodium | 999 | 213 |
| Lisinopril | Lisinopril | 751 | 197 |
| Omeprazole | Omeprazole | 698 | 182 |
| Potassium Chloride | Potassium Chloride | 627 | 122 |
| Eliquis | Apixaban | 612 | 68 |
| Losartan Potassium | Losartan Potassium | 586 | 148 |
| Metformin Hcl | Metformin Hcl | 507 | 108 |
| Gabapentin | Gabapentin | 495 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 484 | 129 |
| Carvedilol | Carvedilol | 470 | 105 |
| Famotidine | Famotidine | 438 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 419 | 98 |
| Donepezil Hcl | Donepezil Hcl | 404 | 59 |
| Furosemide | Furosemide | 401 | 92 |
| Simvastatin | Simvastatin | 397 | 107 |
| Memantine Hcl | Memantine Hcl | 387 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 374 | 83 |
| Buspirone Hcl | Buspirone Hcl | 362 | 59 |
| Trazodone Hcl | Trazodone Hcl | 347 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 346 | 86 |
| Escitalopram Oxalate | Escitalopram Oxalate | 343 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 343 | 72 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 331 | 218 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 297 | 88 |
| Montelukast Sodium | Montelukast Sodium | 290 | 76 |
| Tramadol Hcl | Tramadol Hcl | 289 | 59 |
| Mirtazapine | Mirtazapine | 286 | 50 |
| Sertraline Hcl | Sertraline Hcl | 275 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 269 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 246 | 46 |
| Meloxicam | Meloxicam | 244 | 77 |
| Fluoxetine Hcl | Fluoxetine Hcl | 241 | 53 |
| Alprazolam | Alprazolam | 238 | 31 |
| Clonazepam | Clonazepam | 238 | 40 |
| Metformin Hcl Er | Metformin Hcl | 238 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 233 | 98 |
| Alendronate Sodium | Alendronate Sodium | 229 | 59 |
| Allopurinol | Allopurinol | 220 | 64 |
| Celecoxib | Celecoxib | 211 | 74 |
| Citalopram Hbr | Citalopram Hydrobromide | 208 | 47 |
| Methocarbamol | Methocarbamol | 202 | 76 |
| Methylprednisolone | Methylprednisolone | 202 | 167 |
| Pregabalin | Pregabalin | 200 | 46 |
| Divalproex Sodium | Divalproex Sodium | 195 | 23 |
| Glimepiride | Glimepiride | 195 | 53 |
| Sucralfate | Sucralfate | 194 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 191 | 79 |
| Doxycycline Hyclate | Doxycycline Hyclate | 185 | 113 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 181 | 60 |
| Cefuroxime | Cefuroxime Axetil | 176 | 148 |
| Ropinirole Hcl | Ropinirole Hcl | 175 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 173 | 24 |
| Baclofen | Baclofen | 169 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 166 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 163 | 43 |
| Spironolactone | Spironolactone | 162 | 39 |
| Torsemide | Torsemide | 150 | 41 |
| Ezetimibe | Ezetimibe | 149 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 149 | 33 |
| Amiodarone Hcl | Amiodarone Hcl | 146 | 24 |
| Levetiracetam | Levetiracetam | 142 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 129 | 20 |
| Januvia | Sitagliptin Phosphate | 123 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 123 | 44 |
| Lorazepam | Lorazepam | 120 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 119 | 82 |
| Xarelto | Rivaroxaban | 116 | 16 |
| Prednisone | Prednisone | 115 | 69 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 114 | 17 |
| Bupropion Xl | Bupropion Hcl | 113 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 107 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 104 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 104 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 20 |
| Fluconazole | Fluconazole | 100 | 58 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 99 | 15 |
| Olanzapine | Olanzapine | 99 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 99 | 65 |
| Metoclopramide Hcl | Metoclopramide Hcl | 98 | 17 |
| Risperidone | Risperidone | 97 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 96 | 65 |
| Ozempic | Semaglutide | 95 | 16 |
| Clonidine Hcl | Clonidine Hcl | 93 | 21 |
| Levofloxacin | Levofloxacin | 90 | 59 |
| Pioglitazone Hcl | Pioglitazone Hcl | 90 | 27 |
| Synthroid | Levothyroxine Sodium | 86 | 22 |
| Warfarin Sodium | Warfarin Sodium | 85 | 19 |
| Latanoprost | Latanoprost | 83 | 14 |
| Nystatin | Nystatin | 82 | 51 |
| Entresto | Sacubitril/Valsartan | 80 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 80 | 79 |
| Promethazine Hcl | Promethazine Hcl | 80 | 31 |
| Colchicine | Colchicine | 79 | 19 |
| Bumetanide | Bumetanide | 78 | 20 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 77 | 24 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 77 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 77 | 24 |
| Estradiol | Estradiol | 76 | 24 |
| Jardiance | Empagliflozin | 76 | 13 |
| Mupirocin | Mupirocin | 75 | 56 |
| Primidone | Primidone | 75 | suppressed |
| Ramipril | Ramipril | 74 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 73 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 72 | 13 |
| Colestipol Hcl | Colestipol Hcl | 72 | 13 |
| Myrbetriq | Mirabegron | 72 | 11 |
| Atenolol | Atenolol | 71 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | 11 |
| Meclizine Hcl | Meclizine Hcl | 68 | 35 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 12 |
| Lovastatin | Lovastatin | 64 | 15 |
| Finasteride | Finasteride | 62 | 13 |
| Valacyclovir | Valacyclovir Hcl | 62 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 41 |
| Benazepril Hcl | Benazepril Hcl | 59 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 59 | 12 |
| Propranolol Hcl | Propranolol Hcl | 58 | 12 |
| Azithromycin | Azithromycin | 57 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 55 | 13 |
| Rivastigmine | Rivastigmine Tartrate | 53 | suppressed |
| Glipizide | Glipizide | 52 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 51 | 51 |
| Doxepin Hcl | Doxepin Hcl | 51 | 27 |
| Rexulti | Brexpiprazole | 50 | suppressed |
| Topiramate | Topiramate | 50 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | 12 |
| Linzess | Linaclotide | 49 | 13 |
| Naproxen | Naproxen | 49 | 24 |
| Nifedipine Er | Nifedipine | 49 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 48 | suppressed |
| Valsartan | Valsartan | 47 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 46 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | 11 |
| Sotalol | Sotalol Hcl | 44 | suppressed |
| Sulindac | Sulindac | 43 | 18 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 42 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 42 | 11 |
| Eszopiclone | Eszopiclone | 42 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 42 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Fenofibrate | Fenofibrate | 39 | 12 |
| Anastrozole | Anastrozole | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | 14 |
| Ibuprofen | Ibuprofen | 38 | 18 |
| Novolog | Insulin Aspart | 38 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 37 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 37 | suppressed |
| Verapamil Er | Verapamil Hcl | 37 | 14 |
| Cholestyramine | Cholestyramine (With Sugar) | 36 | 12 |
| Levemir | Insulin Detemir | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Methimazole | Methimazole | 34 | suppressed |
| Cilostazol | Cilostazol | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 32 | 16 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 25 |
| Metolazone | Metolazone | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 11 |
| Phenytoin | Phenytoin | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Humalog | Insulin Lispro | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Betamethasone Valerate | Betamethasone Valerate | 28 | 22 |
| Tradjenta | Linagliptin | 28 | suppressed |
| Verapamil Sr | Verapamil Hcl | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 15 |
| Nabumetone | Nabumetone | 27 | 12 |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Paliperidone Er | Paliperidone | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 26 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Dexamethasone | Dexamethasone | 25 | 24 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Scopolamine | Scopolamine | 25 | 11 |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Insulin Lispro | Insulin Lispro | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Nystop | Nystatin | 21 | 14 |
| Dulera | Mometasone/Formoterol | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Zafirlukast | Zafirlukast | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 18 |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | 15 |
| Ssd | Silver Sulfadiazine | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 17 | 17 |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Multaq | Dronedarone Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Alogliptin | Alogliptin Benzoate | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 16 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Tresiba | Insulin Degludec | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 12 |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Priftin | Rifapentine | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,112.29 · 51 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, IBSRELA, Jornay PM, LEQVIO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, XIFAXAN, ZTLido, Zunveyl | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error